Structure via PubChem · Public domain (PubChem)
memantine
Also known as 3,5-dimethyl-1-adamantanamine, 1,3-dimethyl-5-adamantanamine, 3,5-dimethyl-1-aminoadamantane, 3,5-dimethyltricyclo[3.3.1.1(3,7)]decan-1-amine, 1-amino-3,5-dimethyladamantane, 1,3-dimethylaminoadamantane
Memantine, sold under the brand name Namenda among others, is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is taken by mouth.
Chemical data
- Formula
- C12H21N
- Molecular weight
- 179.3 g/mol
- IUPAC name
- 3,5-dimethyladamantan-1-amine
- SMILES
- CC12CC3CC(C1)(CC(C3)(C2)N)C
- InChIKey
- BUGYDGFZZOZRHP-UHFFFAOYSA-N
- XLogP
- 3.3
- Polar surface area
- 26 Ų
- H-bond donors
- 1
- H-bond acceptors
- 1
- Formal charge
- 0
via PubChem
Research
5,145 papers~19 min read
Article
31 sectionsContents
- Medical uses
- Alzheimer's disease and dementia
- Radiation therapy
- Adverse effects
- Pharmacology
- Pharmacodynamics
- Glutamatergic
- Serotonergic
- Cholinergic
- Dopaminergic
- Sigmaergic
- Other actions
- Pharmacokinetics
- Absorption
- Distribution
- Metabolism
- Elimination
- Chemistry
- History
- Society and culture
- Recreational use
- Brand names
- Research
- Psychiatric disorders
- Parkinson's disease
- Apathy
- Long COVID
- Catatonia
- Autism spectrum disorder
- References
- Further reading
Memantine, sold under the brand name Namenda among others, is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is taken by mouth.
Common side effects include headache, constipation, sleepiness, and dizziness. Severe side effects may include blood clots, psychosis, and heart failure. It is believed to work by acting on NMDA receptors, working as a pore blocker of these ion channels.
